Literature DB >> 24935758

Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels.

Yan Li1, Peder Larson, Albert P Chen, Janine M Lupo, Eugene Ozhinsky, Douglas Kelley, Susan M Chang, Sarah J Nelson.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the feasibility of using a short echo time, three-dimensional H-1 magnetic resonance spectroscopic imaging (MRSI) sequence at 7 Tesla (T) to assess the metabolic signature of lesions for patients with glioma.
METHODS: Twenty-nine patients with glioma were studied. MRSI data were obtained using CHESS water suppression, spectrally selective adiabatic inversion-recovery pulses and automatically prescribed outer-volume-suppression for lipid suppression, and spin echo slice selection (echo time = 30 ms). An interleaved flyback echo-planar trajectory was applied to shorten the total acquisition time (∼10 min). Relative metabolite ratios were estimated in tumor and in normal-appearing white and gray matter (NAWM, GM).
RESULTS: Levels of glutamine, myo-inositol, glycine, and glutathione relative to total creatine (tCr) were significantly increased in the T2 lesions for all tumor grades compared with those in the NAWM (P < 0.05), while N-acetyl aspartate to tCr were significantly decreased (P < 0.05). In grade 2 gliomas, level of total choline-containing-compounds to tCr was significantly increased (P = 0.0137), while glutamate to tCr was significantly reduced (P = 0.0012).
CONCLUSION: The improved sensitivity of MRSI and the increased number of metabolites that can be evaluated using 7T MR scanners is of interest for evaluating patients with glioma. This study has successfully demonstrated the application of a short-echo spin-echo MRSI sequence to detect characteristic differences in regions of tumor versus normal appearing brain.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  7T; glioma; magnetic resonance spectroscopic imaging

Mesh:

Substances:

Year:  2014        PMID: 24935758      PMCID: PMC4269580          DOI: 10.1002/jmri.24672

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  50 in total

1.  SENSE: sensitivity encoding for fast MRI.

Authors:  K P Pruessmann; M Weiger; M B Scheidegger; P Boesiger
Journal:  Magn Reson Med       Date:  1999-11       Impact factor: 4.668

Review 2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

3.  Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells.

Authors:  W Zhong; T Yan; R Lim; L W Oberley
Journal:  Free Radic Biol Med       Date:  1999-12       Impact factor: 7.376

4.  Improved spatial coverage for brain 3D PRESS MRSI by automatic placement of outer-volume suppression saturation bands.

Authors:  Eugene Ozhinsky; Daniel B Vigneron; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

5.  Neurologic 3D MR spectroscopic imaging with low-power adiabatic pulses and fast spiral acquisition.

Authors:  Ovidiu C Andronesi; Borjan A Gagoski; A Gregory Sorensen
Journal:  Radiology       Date:  2011-12-20       Impact factor: 11.105

6.  Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.

Authors:  Adam Elkhaled; Llewellyn E Jalbert; Joanna J Phillips; Hikari A I Yoshihara; Rupa Parvataneni; Radhika Srinivasan; Gabriela Bourne; Mitchel S Berger; Susan M Chang; Soonmee Cha; Sarah J Nelson
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

7.  Automated prescription of oblique brain 3D magnetic resonance spectroscopic imaging.

Authors:  Eugene Ozhinsky; Daniel B Vigneron; Susan M Chang; Sarah J Nelson
Journal:  Magn Reson Med       Date:  2012-06-12       Impact factor: 4.668

8.  Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.

Authors:  Yan Li; Janine M Lupo; Rupa Parvataneni; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

9.  Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.

Authors:  Makoto Ohno; Yoshitaka Narita; Yasuji Miyakita; Yuko Matsushita; Akihiko Yoshida; Shintaro Fukushima; Koichi Ichimura; Soichiro Shibui
Journal:  Brain Tumor Pathol       Date:  2013-03-14       Impact factor: 3.154

10.  IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Authors:  Severina Leu; Stefanie von Felten; Stephan Frank; Erik Vassella; Istvan Vajtai; Elisabeth Taylor; Marianne Schulz; Gregor Hutter; Jürgen Hench; Philippe Schucht; Jean-Louis Boulay; Luigi Mariani
Journal:  Neuro Oncol       Date:  2013-02-13       Impact factor: 13.029

View more
  23 in total

Review 1.  Imaging tumor metabolism using in vivo magnetic resonance spectroscopy.

Authors:  Yan Li; Ilwoo Park; Sarah J Nelson
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

2.  High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T.

Authors:  Gilbert Hangel; Saurabh Jain; Elisabeth Springer; Eva Hečková; Bernhard Strasser; Michal Považan; Stephan Gruber; Georg Widhalm; Barbara Kiesel; Julia Furtner; Matthias Preusser; Thomas Roetzer; Siegfried Trattnig; Diana M Sima; Dirk Smeets; Wolfgang Bogner
Journal:  Neuroimage       Date:  2019-02-14       Impact factor: 6.556

3.  Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

Authors:  Zhongxu An; Vivek Tiwari; Sandeep K Ganji; Jeannie Baxter; Michael Levy; Marco C Pinho; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2017-08-22       Impact factor: 4.668

4.  Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma.

Authors:  Yan Li; Marisa Lafontaine; Susan Chang; Sarah J Nelson
Journal:  ACS Chem Neurosci       Date:  2017-10-16       Impact factor: 4.418

Review 5.  Application of 7T MRS to High-Grade Gliomas.

Authors:  L McCarthy; G Verma; G Hangel; A Neal; B A Moffat; J P Stockmann; O C Andronesi; P Balchandani; C G Hadjipanayis
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-26       Impact factor: 4.966

6.  3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.

Authors:  Zhongxu An; Vivek Tiwari; Jeannie Baxter; Michael Levy; Kimmo J Hatanpaa; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2018-09-14       Impact factor: 4.668

7.  Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.

Authors:  Annabelle Shaffer; Susanna S Kwok; Anant Naik; Aaron T Anderson; Fan Lam; Tracey Wszalek; Paul M Arnold; Wael Hassaneen
Journal:  Front Neurol       Date:  2022-04-05       Impact factor: 4.003

8.  Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations.

Authors:  Andrew A Maudsley; Ovidiu C Andronesi; Peter B Barker; Alberto Bizzi; Wolfgang Bogner; Anke Henning; Sarah J Nelson; Stefan Posse; Dikoma C Shungu; Brian J Soher
Journal:  NMR Biomed       Date:  2020-04-29       Impact factor: 4.044

Review 9.  Accelerated MR spectroscopic imaging-a review of current and emerging techniques.

Authors:  Wolfgang Bogner; Ricardo Otazo; Anke Henning
Journal:  NMR Biomed       Date:  2020-05-12       Impact factor: 4.044

Review 10.  Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field.

Authors:  Giuseppe Barisano; Farshid Sepehrband; Samantha Ma; Kay Jann; Ryan Cabeen; Danny J Wang; Arthur W Toga; Meng Law
Journal:  Br J Radiol       Date:  2018-11-01       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.